OncoMatch/Clinical Trials/NCT07332000
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Is NCT07332000 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies aglatimagene besadenovec + valacyclovir for prostate cancer patients treated by radiotherapy.
Treatment: aglatimagene besadenovec + valacyclovir — Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation therapy (EBRT).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage INTERMEDIATE-RISK (NCCN CRITERIA) (NCCN)
Excluded: Stage REGIONAL LYMPH NODE INVOLVEMENT, DISTANT METASTASES
Participants meeting National Comprehensive Cancer Network (NCCN) intermediate-risk criteria; Regional lymph node involvement or distant metastases [excluded]
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: any prior treatment for prostate cancer
Exception: transurethral resection of the prostate (TURP)
Prior treatment for prostate cancer except transurethral resection of the prostate (TURP). If prior TURP, participants must be deemed able to receive multiple intra-prostatic injections by the Investigator.
Cannot have received: orchiectomy
Participants who had or plan to have orchiectomy as the form of hormonal ablation
Lab requirements
Blood counts
White blood cells > 3000/mm3; Platelets >100,000/mm3
Kidney function
Serum creatinine < 2 mg/dL; Calculated creatinine clearance > 30 mL/min
Liver function
AST < 3 x upper limit of normal
The following laboratory criteria must be met (treatment group only): AST < 3 x upper limit of normal; Serum creatinine < 2 mg/dL; Calculated creatinine clearance > 30 mL/min; White blood cells > 3000/mm3; Platelets >100,000/mm3
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Academic Urology and Urogynecology of Arizona · Peoria, Arizona
- Colorado Clinical Research · Lakewood, Colorado
- Urology Associates · Littleton, Colorado
- Chesapeake Urology Research Associates · Towson, Maryland
- Sheldon Freedman, MD Ltd. · Las Vegas, Nevada
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07332000 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage INTERMEDIATE-RISK (NCCN CRITERIA) is required.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages